🎉 M&A multiples are live!
Check it out!

BioKangtai Valuation Multiples

Discover revenue and EBITDA valuation multiples for BioKangtai and similar public comparables like GSK India, Prescient Therapeutics, and AstraZeneca India.

BioKangtai Overview

About BioKangtai

Shenzhen Kangtai Biological Products Co Ltd is a human vaccine research and development company. The company is engaged in the research and development, production and sales of recombinant hepatitis B vaccine, b -type influenza Haemophilus conjugate vaccine, measles-rubella combined live attenuated vaccine, cell-free baibai broke b Haemophilus influenzae vaccine and other products.


Founded

1992

HQ

China
Employees

n/a

Website

biokangtai.com

Financials

LTM Revenue $419M

LTM EBITDA $127M

EV

$2.5B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

BioKangtai Financials

BioKangtai has a last 12-month revenue of $419M and a last 12-month EBITDA of $127M.

In the most recent fiscal year, BioKangtai achieved revenue of $479M and an EBITDA of $173M.

BioKangtai expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See BioKangtai valuation multiples based on analyst estimates

BioKangtai P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $479M $400M XXX XXX XXX
Gross Profit $367M $366M XXX XXX XXX
Gross Margin 77% 91% XXX XXX XXX
EBITDA $173M $115M XXX XXX XXX
EBITDA Margin 36% 29% XXX XXX XXX
Net Profit $174M -$18.3M XXX XXX XXX
Net Margin 36% -5% XXX XXX XXX
Net Debt n/a $161M XXX XXX XXX

Financial data powered by Morningstar, Inc.

BioKangtai Stock Performance

As of April 15, 2025, BioKangtai's stock price is CNY 15 (or $2).

BioKangtai has current market cap of CNY 16.3B (or $2.2B), and EV of CNY 18.1B (or $2.5B).

See BioKangtai trading valuation data

BioKangtai Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$2.5B $2.2B XXX XXX XXX XXX $0.07

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

BioKangtai Valuation Multiples

As of April 15, 2025, BioKangtai has market cap of $2.2B and EV of $2.5B.

BioKangtai's trades at 6.0x LTM EV/Revenue multiple, and 19.7x LTM EBITDA.

Analysts estimate BioKangtai's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for BioKangtai and 10K+ public comps

BioKangtai Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $2.5B XXX XXX XXX
EV/Revenue 6.2x XXX XXX XXX
EV/EBITDA 21.7x XXX XXX XXX
P/E 44.1x XXX XXX XXX
P/E/Growth 1.1x XXX XXX XXX
EV/FCF n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get BioKangtai Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

BioKangtai Valuation Multiples

BioKangtai's NTM/LTM revenue growth is 14%

BioKangtai's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.

Over next 12 months, BioKangtai's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate BioKangtai's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for BioKangtai and other 10K+ public comps

BioKangtai Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -16% XXX XXX XXX XXX
EBITDA Margin 29% XXX XXX XXX XXX
EBITDA Growth -33% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 43% XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee n/a XXX XXX XXX XXX
S&M Expenses to Revenue 34% XXX XXX XXX XXX
G&A Expenses to Revenue 4% XXX XXX XXX XXX
R&D Expenses to Revenue 14% XXX XXX XXX XXX
Opex to Revenue 54% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

BioKangtai Public Comps

See public comps and valuation multiples for Vaccines & Immunotherapies and Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
CSL XXX XXX XXX XXX XXX XXX
Imugene XXX XXX XXX XXX XXX XXX
Prescient Therapeutics XXX XXX XXX XXX XXX XXX
GSK India XXX XXX XXX XXX XXX XXX
AstraZeneca India XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

BioKangtai M&A and Investment Activity

BioKangtai acquired  XXX companies to date.

Last acquisition by BioKangtai was  XXXXXXXX, XXXXX XXXXX XXXXXX . BioKangtai acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by BioKangtai

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About BioKangtai

When was BioKangtai founded? BioKangtai was founded in 1992.
Where is BioKangtai headquartered? BioKangtai is headquartered in China.
Is BioKangtai publicy listed? Yes, BioKangtai is a public company listed on SHE.
What is the stock symbol of BioKangtai? BioKangtai trades under 300601 ticker.
When did BioKangtai go public? BioKangtai went public in 2017.
Who are competitors of BioKangtai? Similar companies to BioKangtai include e.g. CSL, Imugene, Prescient Therapeutics, GSK India.
What is the current market cap of BioKangtai? BioKangtai's current market cap is $2.2B
What is the current revenue of BioKangtai? BioKangtai's last 12-month revenue is $419M.
What is the current EBITDA of BioKangtai? BioKangtai's last 12-month EBITDA is $127M.
What is the current EV/Revenue multiple of BioKangtai? Current revenue multiple of BioKangtai is 6.0x.
What is the current EV/EBITDA multiple of BioKangtai? Current EBITDA multiple of BioKangtai is 19.7x.
What is the current revenue growth of BioKangtai? BioKangtai revenue growth between 2023 and 2024 was -16%.
Is BioKangtai profitable? Yes, BioKangtai is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.